Physician profile
Jack P Murphy
NPI 1487615662
$6,224.51
in general payments reported to CMS, 2019-2025
29 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what 79% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $500 · 2021: $519 · 2022: $673 · 2023: $648 · 2024: $955 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.09 |
| Education | $139.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,245.33 | 2019-2025 | |
| Pfizer INC. | $768.56 | 2019-2025 | |
| Ucb, INC. | $608.50 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $567.37 | 2019-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $344.00 | 2019-2025 | |
| Leo Pharma INC. | $223.30 | 2020-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $188.18 | 2022-2025 | Ebglyss, Taltz |
| Medimetriks Pharmaceuticals, INC. | $161.34 | 2019-2025 | Clindacin Etz, Neo-Synalar |
| Sun Pharmaceutical Industries INC. | $155.04 | 2020-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $136.80 | 2019-2025 | |
| Galderma Laboratories, L.P. | $102.06 | 2019-2025 | Nemluvio, Dysport |
| Epi Health, LLC | $87.18 | 2019-2022 | |
| Organon LLC | $81.15 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $80.88 | 2023-2025 | Sotyktu |
| Organogenesis INC. | $64.92 | 2023 | Puraply |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $57.56 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.46 | 2021-2023 | Arazlo, Jublia |
| Revance Therapeutics, INC. | $48.97 | 2024 | Daxxify |
| Almirall LLC | $46.57 | 2022-2024 | Klisyri |
| Journey Medical Corporation | $34.49 | 2022-2025 | |
| Amgen INC. | $21.99 | 2025 | Otezla |
| Kerecis Limited | $21.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.47 | 2024 | Spevigo |
| Dermira, INC. | $20.63 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.56 | 2023 | Ycanth |
| Smith+Nephew, INC. | $18.31 | 2020 | |
| Celgene Corporation | $17.14 | 2019 | |
| Elekta, INC. | $15.49 | 2025 | Flexitron Hdr |
| Merz North America, INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.